Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
复制标题
DOI:
10.1016/j.bone.2010.04.594
复制
发表时间:
2010-07-01
期刊:
影响因子:
4.1
通讯作者:
Libanati, C.
中科院分区:
文献类型:
--
作者:
Genant, H. K.;Engelke, K.;Libanati, C.
Background: Bone strength is determined by both cortical and trabecular bone compartments and can be evaluated radiologically through measurement of bone density and geometry. Quantitative computed tomography (QCT) separately assesses cortical and trabecular bone reliably at various sites, including the distal radius where there is a gradation of cortical and trabecular bone. We evaluated the effect of denosumab, a fully human monoclonal antibody that inhibits RANK ligand, on distal radius QCT in women with low bone mass to assess the impact of this novel therapy separately on trabecular and cortical bone.Methods: Postmenopausal women (n=332) with spine areal bone mineral density (BMD) T-scores between -1.0 and -2.5 received denosumab 60 mg or placebo every 6 months during the 24-month study. QCT measurements along the distal radius were made using a whole-body computed tomography scanner and were used to determine the percentage change from baseline in volumetric BMD; volumetric bone mineral content (BMC); cortical thickness; volume; circumference; and density-weighted polar moment of inertia (PMI), a derived index of bone strength.Results: Denosumab treatment significantly increased total BMD and BMC along the radius (proximal, distal, and ultradistal sections). At 24 months, the ultradistal region had the greatest percentage increase in total BMD (4.7% [95% CI, 3.6-5.7]; P